Eli Lilly (NYSE: LLY) has just received US Food and Drug Administration (FDA) approval with its entry into the emerging class of CGRP-inhibitor migraine drugs.
The US drugmaker’s Emgality (galcanezumab) might be behind rivals from Amgen (Nasdaq: AMGN) and Teva Pharmaceutical Industries (NYSE: TEVA) in gaining FDA approval, but it is pulling up some stops to catch up.
Annual sales of $700 million predicted in 2022
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze